The company plans to use results from this study to file for a Humanitarian Device Exemption, or HDE. That exemption is designed to allow use of devices in small patient populations of 4,000 people or less and could come as early as February 2015. It's also working on a device for use in children. Pumping up sales. Abiomed has been around since 1981, but share prices really took off in 2013 thanks to rising demand for the company's Impella product line, which includes catheters, sensors, and pumps used to boost circulation before, during, and after heart surgery.